Want to join the conversation?
$DHR 2Q15 Call: Life Sciences & Diagnostics sales for the quarter were up 3% while core revenue grew 4.5%. Core operating margin increased 55 basis points while reported operating margin decreased 30 basis points to 15.5% due primarily to the dilutive effect of recent acquisitions. Diagnostics platform delivered mid single-digit core revenue growth
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?